What were the main drivers of revenue growth in the second quarter of 2003?

Revenue growth was primarily driven by the Companion Animal Group (CAG), with notable contributions from the new LaserCyte™ hematology system, increased sales of instrument consumables, rapid assay products, and laboratory services. The Food and Environmental Group (FEG) also contributed positively through sales of water testing products.

How did the company's profitability change compared to the prior year?

Profitability showed significant improvement. Gross profit margin increased to 49% from 47%, and operating income rose by 30% year-over-year for the quarter. This was due to increased sales volume, a favorable product mix, and operational efficiencies, partially offset by costs related to new product introductions like LaserCyte™.

What is the company's liquidity and cash flow situation?

IDEXX maintained a strong liquidity position with $151.4 million in cash and cash equivalents as of June 30, 2003. Cash flow from operations was robust, providing $65.6 million for the first half of the year, which supported investments in capital expenditures and ongoing share repurchase programs.

Are there any significant new developments or risks highlighted in the filing?

A significant development is the formation of a joint venture in China to market veterinary diagnostic products. Key risks mentioned include intense competition, reliance on proprietary technologies, supply chain dependencies for certain components, regulatory hurdles for pharmaceutical products, and the potential impact of distributor inventory fluctuations on quarterly results.

IDXX 10-Q Quarterly Report Q2 FY2003 — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. (IDXX) reported strong financial performance for the second quarter and first half of 2003. Revenue increased by 15% year-over-year in the second quarter, reaching $121.8 million, driven primarily by the Companion Animal Group (CAG) segment, which represents about 80% of sales. The introduction of the LaserCyte™ hematology system and continued growth in instrument consumables, rapid assays, and laboratory services were key contributors. The Food and Environmental Group (FEG) also showed growth, albeit at a slower pace. Profitability improved significantly, with gross profit margins increasing to 49% in the second quarter, up from 47% in the prior year. Operating income surged by 30% year-over-year for the quarter, reflecting effective cost management and increased revenue. Diluted earnings per share rose to $0.47 for the quarter from $0.37 in the prior year. The company's liquidity remains strong, with substantial cash and equivalents, and operating cash flow is healthy, supporting continued investment in growth initiatives and share repurchases.

Key Highlights

1Total revenue grew 15% to $121.8 million for the second quarter of 2003 compared to the prior year.
2Companion Animal Group (CAG) revenue increased 17% to $98.8 million, driven by new product introductions (LaserCyte™) and strong performance in consumables, rapid assays, and lab services.
3Gross profit margin improved to 49% from 47% in the prior year's second quarter, indicating better cost control and product mix.
4Operating income increased by 30% to $24.3 million for the second quarter, demonstrating strong operational leverage.
5Diluted earnings per share (EPS) rose to $0.47 for the second quarter, up from $0.37 in the prior year.
6The company maintained a strong cash position with $151.4 million in cash and cash equivalents as of June 30, 2003.
7A new joint venture was formed in China for veterinary diagnostic products, expanding international reach.
8Share repurchases continued, with $23.5 million spent on treasury stock in the first half of 2003.

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2003

Summary

Key Highlights

Frequently Asked Questions